­
­
­
­

Inventi Impact - Biomedical Analysis

Articles

  • Inventi:pba/17125/15
    REVERSED PHASE HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF SUMATRIPTAN SUCCINATE NANOPARTICLES IN RAT PLASMA AND BRAIN HOMOGENATE
    Girotra Priti Hansraj, Shailendra Kumar Singh*, Gaurav Kumar

    A rapid, specific and precise reversed phase high performance liquid chromatographic method, with UV detection, was developed for the quantification of sumatriptan succinate loaded in chitosan solid lipid nanoparticles in rat plasma and brain homogenate samples. Rizatriptan benzoate was used as the internal standard and an efficient liquid-liquid extraction technique was employed for extraction from the plasma and brain homogenates. The drug was analyzed by reversed phase C18 column, using 0.05 M potassium dihydrogen orthophosphate solution (containing 10% v/v acetonitrile, 0.1% v/v triethylamine and pH adjusted to 3.8 with o-phosphoric acid) and acetonitrile in a ratio of 80:20, at a flow rate of 1 ml/min and detection wavelength of 226 nm. The developed method was validated for linearity, precision, accuracy, limit of detection (LOD), limit of quantification (LOQ), robustness and specificity. The method was found to be linear in the concentration range of 1.25-8.75 μg/ml and 2.5-17.5 μg/g for plasma and brain homogenates respectively. The other validation parameters were found to be within the acceptable limit (% RSD less than 2%). LOD and LOQ were obtained as 80 ng/ml and 250 ng/ml respectively. The present developed and validated RP-HPLC method thus offers extensive applicability in bioavailability studies involving sumatriptan succinate in nanoparticles.

    How to Cite this Article
    Girotra Priti Hansraj, Shailendra Kumar Singh, Gaurav Kumar. Reversed Phase HPLC Method Development and Validation for the Quantification of Sumatriptan Succinate Nanoparticles in Rat Plasma and Brain Homogenate. Inventi Impact: Biomedical Analysis, 2016(1):1-5, 2016.
    Download Full Text